AUS
NZ
UK
CA
USA
IND
Highlights
- Tryptamine Therapeutics expands its clinical team with top experts
- Focus intensifies on innovative psilocin-based treatment development
- Preparations underway for groundbreaking binge eating disorder trial
Tryptamine Therapeutics (ASX:TYP) has reinforced its commitment to pioneering psychedelic-assisted therapies with the strategic addition of two highly regarded professionals to its clinical development team. The appointments come at a critical time as the company prepares for a world-first trial of its lead drug candidate, TRP-8803, in collaboration with Swinburne University. While not a part of the ASX 200 companies, the company is steadily attracting interest through its specialised research in mental health and innovative treatment approaches.
Joining the team are Professor Marcel Mozafari as a full-time senior formulation scientist and Professor David Castle as a part-time consultant medical officer. Both professionals bring decades of experience and are based in Australia, a move expected to streamline operations and support a more cost-effective research environment.
Professor Mozafari is recognised globally for his work in pharmaceutical nanotechnology and has contributed extensively to drug formulation strategies. His scientific leadership is anticipated to enhance the development of TRP-8803, which is designed to deliver psilocin via intravenous infusion—a novel method aiming to improve upon the limitations of oral psilocybin.
Meanwhile, Professor Castle adds significant depth to the medical oversight of the program. With a strong background in psychiatric research and clinical studies on psychedelic therapies, his insight is aligned with the company’s objective to integrate psychotherapy with scientifically backed treatment delivery.
Tryptamine Therapeutics is focused on developing novel psychedelic compounds, particularly psilocin-based formulations, to address a range of unmet medical conditions. TRP-8803 has been specifically designed to optimise the patient experience by reducing onset delays and enhancing control over the therapeutic effects during treatment. This formulation also aims to shorten intervention times, creating a more scalable and accessible treatment model.
The company has already completed trials using a predecessor compound, TRP-8802, in areas such as binge eating disorder, fibromyalgia, and irritable bowel syndrome. As research transitions toward TRP-8803, the expectation is that future studies will further validate its potential for improved patient outcomes.
With its clinical program expanding and new expert leadership in place, Tryptamine Therapeutics is positioning itself at the forefront of psychedelic-assisted therapy development. The upcoming trial with Swinburne University marks a significant milestone in its pursuit of innovative mental health solutions.
